

Neuralstem, Inc.  
Form 424B3  
May 06, 2013

SUPPLEMENT No. 2

DATED MAY 6, 2013                      Rule 424(b)(3)

(To Prospectus dated May 11, 2010) Registration No. 333-165973

## NEURALSTEM, INC.

### *5,163,956 Shares of Common Shares*

This prospectus supplement (“Supplement”) modifies, supersedes and supplements information contained in, and should be read in conjunction with, that certain prospectus, dated May 11, 2010, related to the resale of our common stock from time to time by certain shareholders (“Prospectus”), of Neuralstem, Inc. (“Company”). This supplement is not complete without, and may not be delivered or used except in connection with, the Prospectus and all supplements thereto.

The information contained in this Supplement modifies and supersedes, in part, the information in the Prospectus, as supplemented. Any information that is modified or superseded in the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this Supplement.

We may amend or supplement the Prospectus from time to time by filing amendments or supplements as required. You should read the entire Prospectus and any amendments or supplements carefully before you make an investment decision.

**Investing in our common stock involves a high degree of risk. You are urged to read the section entitled “Risk Factors” beginning on page 3 of the Prospectus, which describes specific risks and other information that should be considered before you make an investment decision.**

## FORWARD-LOOKING STATEMENTS

You should carefully consider the risk factors set forth in the prospectus, as well as the other information contained in this supplement and the prospectus. This supplement and the prospectus contain forward-looking statements regarding events, conditions, and financial trends that may affect our plan of operation, business strategy, operating results, and financial position. You are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Actual results may differ materially from those included within the forward-looking statements as a result of various factors. Cautionary statements in the “Risk Factors” section of the prospectus identify important risks and uncertainties affecting our future, which could cause actual results to differ materially from the forward-looking statements made in this supplement and the prospectus.

## REPRICING OF WARRANTS

On May 1, 2013, we received a proposal from Andrew Lessman (“Holder”). Pursuant to the proposal, the Holder agreed to exercise Holder’s Class C warrant to purchase 440,000 shares of the Company’s common stock (“Warrant”), for cash, in exchange for the Company: (i) reducing the exercise price of the Warrant from \$2.13 to \$1.07, and (ii) issuing Holder a replacement warrant to purchase 440,000 shares of common shares (“Replacement Warrant”). The terms of the Replacement Warrant are substantially similar to the Warrant, other than having an exercise price of \$1.25 and an expiration date of May 1, 2016.

This Supplement is being filed to reduce the exercise price of the Warrant from \$2.13 to \$1.07.

	No. of Shares
Holder	Underlying Warrant
Andrew Lessman	440,000
Total	440,000